Bayer dented by slow quarter and gloomy outlook

11 May 2023
bayer_large

German life sciences company Bayer (BAYN: DE) was trading 7% lower in mid-afternoon activity on Thursday after presenting its first-quarter 2023 financial results and latest outlook for 2023 as a whole.

The group described a slow start to the year, with sales 1.7% lower than they were in the first quarter of 2023, at 14.39 billion euros ($15.7 billion). Earnings before interest, taxes, depreciation and amortization during the quarter declined 14.9% to 4.47 billion euros, below the average analyst estimate of 4.63 billion euros in a consensus posted on Bayer’s website.

Chinese pharma sales down

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical